Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
77 hot topic(s) found with the query "Sudden death"

Hypertrophic Cardiomyopathy (HCM) and Family Health History of Sudden Death
CDC, December 2022 (Posted: Dec-08-2022 9AM)

If you have a family member, especially a parent, sibling, or child, who died suddenly before age 40, let your doctor know. You might need to be screened for HCM, a genetic condition that causes the heart muscle to become thick and can lead to sudden death. While some people with HCM are very sick, many people, especially children, teens, and young adults, have no or few symptoms and may not know they have a heart problem. Sharing your family history with your doctor can help you and other relatives find HCM early.

Genetic Determinants of Sudden Unexpected Death in Pediatrics.
Koh Hyun Yong et al. Genetics in medicine : official journal of the American College of Medical Genetics 2022 1 (4) 839-850 (Posted: Apr-14-2022 2PM)

We identified likely contributory variants in 37 of 352 probands (11%). Analysis of SUDP genes identified pathogenic/likely pathogenic variants in 12 of 352 cases (SCN1A, DEPDC5 [2], GABRG2, SCN5A [2], TTN [2], MYBPC3, PLN, TNNI3, and PDHA1) and variants of unknown significance–favor-pathogenic in 17 of 352 cases. Exome-wide analyses of the 73 cases with family data additionally identified 4 de novo pathogenic/likely pathogenic variants. We provide strong evidence for a role of genetic factors in SUDP, involving both candidate genes and novel genes for SUDP and expanding phenotypes of disease genes not previously associated with sudden death.

Racial Disparities in Ion Channelopathies and Inherited Cardiovascular Diseases Associated With Sudden Cardiac Death
M Chahine et al, May 2022 (Posted: Mar-06-2022 7AM)

Cardiovascular disease (CVD) continues to be the most common cause of death worldwide, and cardiac arrhythmias account for approximately one half of these deaths. The morbidity and mortality from CVD have been reduced significantly over the past few decades; however, disparities in racial or ethnic populations still exist. This review is based on available literature to date and focuses on known cardiac channelopathies and other inherited disorders associated with sudden cardiac death in African American/Black subjects and the role of epigenetics in phenotypic manifestations of CVD, and illustrates existing disparities in treatment and outcomes. The review also highlights the knowledge gaps that limit understanding of the manifestation of phenotypic abnormalities across racial or ethnic groups and discusses disparities associated with device underuse in the management of patients at risk for sudden cardiac death.

Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility
J Barc et al, Nature Genetics, February 24, 2022 (Posted: Feb-25-2022 9AM)

Brugada syndrome (BrS) is a cardiac arrhythmia disorder associated with sudden death in young adults. With the exception of SCN5A, encoding the cardiac sodium channel NaV1.5, susceptibility genes remain largely unknown. Here we performed a genome-wide association meta-analysis comprising 2,820 unrelated cases with BrS and 10,001 controls, and identified 21 association signals at 12 loci (10 new). Single nucleotide polymorphism (SNP)-heritability estimates indicate a strong polygenic influence. Polygenic risk score analyses based on the 21 susceptibility variants demonstrate varying cumulative contribution of common risk alleles among different patient subgroups, as well as genetic associations with cardiac electrical traits and disorders in the general population.

De novo mutations in childhood cases of sudden unexplained death that disrupt intracellular Ca regulation.
Halvorsen Matthew et al. Proceedings of the National Academy of Sciences of the United States of America 2021 12 (52) (Posted: Dec-28-2021 7AM)

Sudden unexplained death in childhood (SUDC) is an understudied problem. Whole-exome sequence data from 124 "trios" (decedent child, living parents) was used to test for excessive de novo mutations (DNMs) in genes involved in cardiac arrhythmias, epilepsy, and other disorders. Among decedents, nonsynonymous DNMs were enriched in genes associated with cardiac and seizure disorders relative to controls (odds ratio = 9.76).

A college student’s near fatal collapse uncovered a frightening family legacy
SG Boodman, Washington Post, August 23, 2021 (Posted: Aug-24-2021 8AM)

Half of CPVT cases are believed to result from a mutation in the RYR2 gene that provides instructions for proteins that help maintain a regular heartbeat. It is typically inherited in an autosomal dominant manner: a parent with the gene has a 50 percent chance of passing it on to a child. The arrhythmia is estimated to affect about 1 in 10,000 people and believed to be a major cause of sudden death in children and young adults who don’t have other abnormalities, such as an enlarged heart.

Genomic Autopsy of Sudden Deaths in Young Individuals
G Webster et al, JAMA Cardiology, August 13, 2021 (Posted: Aug-14-2021 8AM)

In this cohort study of 103 decedents from a national collaboration of medical examiners, pathogenic/likely pathogenic variants in arrhythmia or cardiomyopathy genes were identified in 13%. In multivariate analysis, rare variants in cardiac genes (pathogenic/likely pathogenic/uncertain significance) were associated with younger age at death.

Genetic Variants Associated With Unexplained Sudden Cardiac Death in Adult White and African American Individuals
L Guo et al, JAMA Cardiology, June 2, 2021 (Posted: Jun-02-2021 10PM)

In this genetic association study of 413 adults who had unexplained SCD, nearly one-fifth of individuals had pathogenic or likely pathogenic genetic variants consistent with inherited cardiomyopathies or arrhythmia syndromes, despite having normal cardiac findings. These clinically significant variants were predominantly associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and long QT syndrome.

Inherited cardiac arrhythmias
PJ Shwartz et al, Nat Rev Dis Primers, July 2020 (Posted: Jul-26-2020 7AM)

The main inherited cardiac arrhythmias are long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia and Brugada syndrome. These rare diseases are often the underlying cause of sudden cardiac death in young individuals and result from mutations in several genes encoding ion channels or proteins involved in their regulation.

Identification of a Novel Homozygous Multi-Exon Duplication in RYR2 Among Children With Exertion-Related Unexplained Sudden Deaths in the Amish Community
DJ Tester et al, JAMA Cardiology, January 8, 2020 (Posted: Jan-09-2020 8AM)

Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases.
Salfati Elias L et al. Genome medicine 2019 Dec (1) 83 (Posted: Dec-19-2019 9AM)

Initial analysis revealed diagnostic variants in 13 rare disease cases (25.4%) and 5 sudden death cases (10%). Re-analysis resulted in the identification of additional diagnostic variants in 3 rare disease cases (5.9%) and 1 sudden unexplained death case (2%), which increased our molecular diagnostic yield to 31.4% and 12%, respectively.

Rare Risk: Newly identified gene variants linked to increased risk for sudden cardiac death
Harvard Medical School, November 2019 (Posted: Nov-28-2019 9AM)

Sudden cardiac death affects 220,000 U.S. adults annually, most of whom have no prior symptoms of a heart issue. By identifying rare DNA variants that substantially increase risk of sudden cardiac death, researchers laid the foundation for efforts to identify individuals who could benefit from prevention strategies prior to experiencing symptoms.

Rare Genetic Variants Associated With Sudden Cardiac Death in Adults
AV Khera et al, JACC, November 2019 (Posted: Nov-17-2019 7AM)

Predicting Risk for Adult-Onset Sudden Cardiac Death in the Population
CR Bezzina et al, JACC, November 16, 2019 (Posted: Nov-17-2019 7AM)

Learn What CDC Is Doing About Sudden Unexpected Infant Death (SUID)
CDC, 2019 Brand (Posted: Oct-07-2019 10AM)

CDC resources and activities include the Sudden Unexpected Infant Death (SUID) and Sudden Death in the Young (SDY) Case Registry, the Sudden Unexplained Infant Death Investigation Reporting Form (SUIDIRF), the 1,000 Grandmothers project, publications and more.

Genetics of Unexplained Sudden Cardiac Death in Adult Caucasian and African American Individuals Living in the State of Maryland
L Guo et al, MedRXIV, September 24, 2019 (Posted: Sep-26-2019 8AM)

This study represents the largest examination reported on the association between cardiomyopathy and arrhythmia P/LP genetic variants and unexplained-SCD in adults with no gross abnormality on rigorous pathological examination. Nearly one-third of those with unexplained-SCD were carriers of P/LP variants.

Lessons learned from testing cardiac channelopathy and cardiomyopathy genes in individuals who died suddenly: A two-year prospective study in a large medical examiner's office with an in-house molecular genetics laboratory and genetic counseling services.
Williams Nori et al. Journal of genetic counseling 2019 Aug (Posted: Aug-24-2019 4PM)

This is a comprehensive review and analysis of 254 cases tested consecutively in the in-house College of American Pathologist-accredited molecular genetics laboratory within the New York City Office of Chief Medical Examiner between October 2015 and February 2018, using a multigene cardiac panel composed of 95 genes.

Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders
Cerrone Marina et al. Circulation 2019 08 (7) 595-610 (Posted: Aug-17-2019 9AM)

Inheritable cardiac disorders are often associated with increased risk of sudden death in the young. In recent years, through genotype-phenotype studies and methodological advances in genetics, it has become evident that most inheritable cardiac disorders are not monogenic but, rather, have a complex genetic basis.

Cardiac Evaluation of Children With a Family History of Sudden Death.
Webster Gregory et al. Journal of the American College of Cardiology 2019 Aug 74(6) 759-770 (Posted: Aug-14-2019 8AM)

After sudden death occurs in the young, first-degree family members should undergo clinical screening for occult cardiac disease, but the diagnostic yield from screening is not well-defined in the United States.This study determined the clinical predictors of cardiac diagnosis in children referred for evaluation following a sudden death in the family.

Cardiovascular genomics and sudden cardiac death in the young.
Isbister Julia et al. Australian journal of general practice 2019 Mar 48(3) 90-95 (Posted: Jul-02-2019 9AM)

Sudden cardiac death in the young is a rare consequence of a number of genetic cardiovascular disorders. The care of survivors of cardiac arrest and families affected by SCD seeks to prevent further SCD events through family screening. The aim of this article is to review the genetic basis of SCD in the young and outline the clinical aspects of caring for families affected by SCD. Inherited cardiomyopathies and primary arrhythmia syndromes are important causes of SCD in young people.

European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death
F Fellmann et al, EJHG, June 24, 2019 (Posted: Jun-24-2019 9AM)

Increasing the proportion of both medicolegal and medical autopsy in case of sudden, unexpected natural death should be a major objective. This should be mandatory for deaths under the age of 40, it should be considered for deaths between ages 40 and 65, and evaluated on a case by case basis after age 65

Cases in Precision Medicine: Genetic Assessment After a Sudden Cardiac Death in the Family
R Laracuente et al, Ann Int Medicine, May 14, 2019 (Posted: May-15-2019 10AM)

Usefulness of Genetic Testing in Sudden Cardiac Arrest Survivors With or Without Previous Clinical Evidence of Heart Disease.
Asatryan Babken et al. The American journal of cardiology 2019 Mar (Posted: Apr-17-2019 9AM)

It took more than a decade to explain the sudden death of my precious teenage son
K Gardner, the Guardian, February 22, 2019 (Posted: Feb-24-2019 1PM)

Genetic testing in sudden unexpected natural death in the young: New York City Office of Chief Medical Examiner's experience and perspective.
Tang Yingying et al. Forensic science, medicine, and pathology 2018 Dec (Posted: Dec-19-2018 10AM)

Outcomes of Cardiac Screening in Adolescent Soccer Players.
Malhotra Aneil et al. The New England journal of medicine 2018 Aug (6) 524-534 (Posted: Aug-09-2018 8AM)

Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies
SM Al-Khatib et al, JAMA Cardiology, June 27, 2018 (Posted: Jun-29-2018 1PM)

Bringing Autopsies Into the Molecular Genetic Era.
Judge Daniel P et al. Circulation 2018 Jun (25) 2727-2729 (Posted: Jun-21-2018 8AM)

Importance of Variant Interpretation in Whole-Exome Molecular Autopsy: Population-Based Case Series.
Shanks Garrett W et al. Circulation 2018 Jun (25) 2705-2715 (Posted: Jun-21-2018 8AM)

Role of genetic heart disease in sentinel sudden cardiac arrest survivors across the age spectrum.
Giudicessi John R et al. International journal of cardiology 2018 May (Posted: Jun-11-2018 11AM)

Unexplained cardiac arrest: a tale of conflicting interpretations of KCNQ1 genetic test results.
Chua Han Chow et al. Clinical research in cardiology : official journal of the German Cardiac Society 2018 Mar (Posted: Apr-04-2018 11AM)

Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.
Waldmann Victor et al. European heart journal 2018 Mar (Posted: Mar-27-2018 1PM)

Cardiac Genetic Predisposition in Sudden Infant Death Syndrome.
Tester David J et al. Journal of the American College of Cardiology 2018 Mar 71(11) 1217-1227 (Posted: Mar-21-2018 4PM)

Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice.
Mates Jesus et al. European journal of human genetics : EJHG 2018 Mar (Posted: Mar-09-2018 9AM)

Coronary Artery Abnormalities as the Cause of Sudden Cardiac Death: A 20-Year Review.
Pawlowicz Bernard et al. The American journal of forensic medicine and pathology 2018 Feb (Posted: Feb-26-2018 9AM)

Applying High-Resolution Variant Classification to Cardiac Arrhythmogenic Gene Testing in a Demographically Diverse Cohort of Sudden Unexplained Deaths.
Lin Ying et al. Circulation. Cardiovascular genetics 2017 Dec 10(6) (Posted: Dec-20-2017 0PM)

Yield and Pitfalls of Ajmaline Testing in the Evaluation of Unexplained Cardiac Arrest and Sudden Unexplained Death
R Tadros et al, JACC CLin Electrophysiology, Dec 2017 (Posted: Dec-18-2017 9AM)

Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology.
Basso Cristina et al. Virchows Archiv : an international journal of pathology 2017 Dec 471(6) 691-705 (Posted: Dec-13-2017 9AM)

Sudden Cardiac Arrest During Competitive Sports
American College of Cardiology, Nov 30, 2017 (Posted: Dec-01-2017 10AM)

Sudden Cardiac Death in Genetic Cardiomyopathies.
Atteya Gourg et al. Cardiac electrophysiology clinics 2017 Dec 9(4) 581-603 (Posted: Nov-29-2017 10AM)

Sudden Cardiac Arrest during Participation in Competitive Sports.
Landry Cameron H et al. The New England journal of medicine 2017 Nov (20) 1943-1953 (Posted: Nov-16-2017 8AM)

Massively Parallel Sequencing of Genes Implicated in Heritable Cardiac Disorders: A Strategy for a Small Diagnostic Laboratory.
Leong Ivone U S et al. Medical sciences (Basel, Switzerland) 2017 Oct 5(4) (Posted: Nov-08-2017 9AM)

Clinical and Genetic Diagnosis of Nonischemic Sudden Cardiac Death.
Jiménez-Jáimez Juan et al. Revista espanola de cardiologia (English ed.) 2017 Oct 70(10) 808-816 (Posted: Oct-04-2017 10AM)

Long QT syndrome and sudden unexpected infant death.
Van Niekerk Chantal et al. Journal of clinical pathology 2017 Sep 70(9) 808-813 (Posted: Sep-27-2017 9AM)

Death and Cardiac Arrest in U.S. Triathlon Participants, 1985 to 2016: A Case Series
KM Harris et al, Ann Int Med, Sep 2017 (Posted: Sep-19-2017 9AM)

Investigating the Genetic Causes of Sudden Unexpected Death in Children Through Targeted Next-Generation Sequencing Analysis.
Dewar Laura J et al. Circulation. Cardiovascular genetics 2017 Aug 10(4) (Posted: Aug-23-2017 9AM)

Postmortem genetic analysis of sudden unexpected death in infancy: neonatal genetic screening may enable the prevention of sudden infant death.
Oshima Yuki et al. Journal of human genetics 2017 Jul (Posted: Aug-02-2017 8AM)

Genetic Testing in the Evaluation of Unexplained Cardiac Arrest: From the CASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry).
Mellor Greg et al. Circulation. Cardiovascular genetics 2017 Jun 10(3) (Posted: Jun-14-2017 10AM)

Relevance of molecular testing in patients with a family history of sudden death.
Kauferstein Silke et al. Forensic science international 2017 Apr 27618-23 (Posted: May-10-2017 10AM)

Postmortem genetic testing should be recommended in sudden cardiac death cases due to thoracic aortic dissection.
Gago-Díaz Marina et al. International journal of legal medicine 2017 Apr (Posted: Apr-12-2017 8AM)

Exome sequencing-based molecular autopsy of formalin-fixed paraffin-embedded tissue after sudden death
RD Bagnall et al, Genetics in Medicine, March 23, 2017 (Posted: Mar-23-2017 1PM)

The Sudden Death in the Young Case Registry: Collaborating to Understand and Reduce Mortality.
Burns Kristin M et al. Pediatrics 2017 Mar 139(3) (Posted: Mar-08-2017 8AM)

Genetic Insurance Discrimination in Sudden Arrhythmia Death Syndromes: Empirical Evidence From a Cross-Sectional Survey in North America.
Mohammed Saira et al. Circulation. Cardiovascular genetics 2017 Jan 10(1) (Posted: Feb-01-2017 11AM)

Sudden death warning over faulty heart gene
BBC February 1, 2017 (Posted: Feb-01-2017 7AM)

Postmortem Genetic Testing for Sudden Unexpected Death.
Schrodi Steven J et al. JAMA 2017 Jan 317(3) 320-321 (Posted: Jan-25-2017 9AM)

How to develop a clinic for sudden cardiac arrest survivors and families of non-survivors.
Abrams Dominic J et al. Cardiology in the young 2017 Jan 27(S1) S3-S9 (Posted: Jan-18-2017 10AM)

Natural and Undetermined Sudden Death: Value of Post-Mortem Genetic Investigation.
Sanchez Olallo et al. PloS one 2016 11(12) e0167358 (Posted: Dec-14-2016 0PM)

Sudden cardiac death of teen reminds physicians of promises, challenges of precision medicine
T Klein, Mayo Clinic, October 31, 2016 (Posted: Nov-01-2016 8AM)

The Role of Genetic Testing in the Identification of Young Athletes with Inherited Primitive Cardiac Disorders at Risk of Exercise Sudden Death.
Tiziano Francesco Danilo et al. Frontiers in cardiovascular medicine 2016 28 (Posted: Oct-16-2016 8AM)

Sudden Death in the Young (SDY) Case Registry
Brand (Posted: Oct-13-2016 9AM)

Sudden death and cardiac arrest without phenotype: the utility of genetic testing.
Wijeyeratne Yanushi D et al. Trends in cardiovascular medicine 2016 Aug (Posted: Oct-12-2016 8PM)

Molecular Autopsies ID Genetic Suspects in Cases of Sudden Death
GEN News Highlights, October 12, 2016 (Posted: Oct-12-2016 8PM)

How genetic sequencing can unlock secret DNA mutations — and save lives
PBS Newshour, May 13, 2016 (Posted: May-14-2016 10AM)

Genetic testing and genetic counseling in patients with sudden death risk due to heritable arrhythmias.
Spoonamore Katherine G et al. Heart rhythm : the official journal of the Heart Rhythm Society 2015 Nov (Posted: Jan-06-2016 11AM)

Prediction of Sudden Cardiac Death with Automated High-Throughput Analysis of Heterogeneity in Standard Resting 12-Lead Electrocardiogram.
Kenttä Tuomas V et al. Heart rhythm : the official journal of the Heart Rhythm Society 2015 Nov (Posted: Jan-06-2016 11AM)

Frequently Asked Questions about the Sudden Death in the Young Case Registry
CDC and NHLBI collaboration Brand (Posted: Sep-09-2015 9AM)

Genetic screening in sudden cardiac death in the young can save future lives.
Stattin Eva-Lena et al. Int. J. Legal Med. 2015 Jul 31. (Posted: Aug-04-2015 2PM)

Utility and limitations of exome sequencing as a genetic diagnostic tool for conditions associated with pediatric sudden cardiac arrest/sudden cardiac death.
Li Mindy H et al. Hum. Genomics 9(1) 15 (Posted: Jul-22-2015 0PM)

Ethics of preparticipation cardiovascular screening for athletes.
Maron Barry J et al. Nat Rev Cardiol 2015 Jun (6) 375-378 (Posted: Jul-18-2015 7PM)

Diseases of the Aorta in Elite Athletes.
Iskandar Aline et al. Clin Sports Med 2015 Jul (3) 461-72 (Posted: Jul-18-2015 7PM)

Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy.
Alpert Craig et al. Clin Sports Med 2015 Jul (3) 489-505 (Posted: Jul-18-2015 7PM)

Genetic Mutation In Heart Proteins May Be Why Some Experience Sudden Cardiac Death During Exercise And Sleep
Dana Dovey, Medical Express, July 16, 2015 (Posted: Jul-18-2015 7PM)

Differential thermosensitivity in mixed syndrome cardiac sodium channel mutants
M Abdelsayed et al. J Physiology, July 2015 (Posted: Jul-18-2015 7PM)

Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: identification of a MYH7 mutation and MYBPC3 mutations.
Kadota Chika et al. J. Hum. Genet. 2015 Jul 16. (Posted: Jul-18-2015 7PM)

Sudden cardiac death in athletes.
Semsarian Christopher et al. Br J Sports Med 2015 Aug (15) 1017-23 (Posted: Jul-18-2015 7PM)

Can sudden cardiac death of the young be prevented?
Brand (Posted: Feb-25-2015 0PM)

Approval of Osimertinib and Necitumumab Increases Lung Cancer Treatment Options
Brand (Posted: Jan-11-2014 11AM)

Last month, the Food and Drug Administration (FDA) approved two targeted therapies for patients with advanced non-small cell lung cancer (NSCLC). The agency approved osimertinib (Tagrisso?) for patients who have developed the epidermal growth factor receptor (EGFR) T790M mutation in their tumors after prior treatment with an EGFR-targeted therapy, and necitumumab (Portrazza?), in combination with standard chemotherapy drugs, for the initial treatment of patients with metastatic squamous NSCLC. Although both drugs target the EGFR gene, to be eligible to receive osimertinib, patients must have the EGFR T790M mutation, while all patients with squamous NSCLC are eligible to receive necitumumab. Osimertinib, part of a class of drugs known as tyrosine kinase inhibitors, received an accelerated approval based on results from two single-arm clinical trials that collectively enrolled 411 patients. All patients in the trials had advanced NSCLC with tumors that harbored the EGFR T790M mutation and whose disease had gotten worse after they were treated with an EGFR-blocking drug. In both trials, a complete or partial reduction in tumor size was seen in approximately 60 percent of patients. Diarrhea and skin and nail conditions, including rash, were among the most common side effects in patients treated with osimertinib. Serious adverse events included inflammation and scarring in the lungs (interstitial lung disease). In conjunction with the osimertinib approval, the agency also approved a companion diagnostic test, the cobas EGFR Mutation Test v2, to test patient?s tumors for the presence of the T790M mutation. ?The majority of patients develop progression of their disease eventually after being treated with an EGFR-targeted kinase inhibitor,? explained Shakun Malik, M.D., of NCI?s Division of Cancer Treatment and Diagnosis. Patients whose tumors progress after receiving these drugs have no other approved options, except for non-targeted chemotherapy, Dr. Malik noted. The T790M mutation is a common resistance mutation in such patients, she continued, so osimertinib?s accelerated approval ?meets an important clinical need.? Phase III trials that confirm osimertinib improves outcomes such as progression-free and overall survival must be completed for the drug to receive regular approval. Necitumumab, a monoclonal antibody, was approved for use in combination with two other standard chemotherapy drugs, gemcitabine and cisplatin, as an initial treatment of patients with advanced squamous NSCLC. The necitumumab approval was based on the results of a large randomized clinical trial that enrolled nearly 1,100 patients with advanced squamous NSCLC. Patients treated with necitumumab along with gemcitabine and cisplatin had a modest improvement in median overall survival compared with patients who received cisplatin and gemcitabine alone: 11.5 months versus 9.9 months. Common side effects associated with necitumumab include skin rash and magnesium deficiency (hypomagnesemia). The FDA also required the drug?s label to include a black box warning to alert clinicians and patients to the risk of cardiac arrest and sudden death associated with necitumumab treatment. Cancer


Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Genomics and Precision Public Health to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP